Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant for excessive daytime sleepiness in Parkinson's disease
2009-013885-14Phase 3Completed
- Sponsor
- Bioprojet
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pitolisant in Excessive Daytime Sleepiness (EDS) (3 arms), sponsored by Bioprojet. Primary endpoints: Change from baseline in Epworth Sleepiness Scale score at Week 12 and Change from baseline in Epworth Sleepiness Scale score at Week 51. Started Sep 2009; status: completed.
02
Drugs
pitolisant
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on 2009-013885-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013885-14.